Ovascience Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
-
277.00
653.00
295.00
Cost of Goods Sold (COGS) incl. D&A
231.00
450.00
2,249.00
5,401.00
2,440.00
Gross Income
231.00
450.00
1,972.00
4,748.00
2,145.00
SG&A Expense
28,503.00
47,483.00
70,027.00
70,864.00
44,431.00
EBIT
28,734.00
47,933.00
71,999.00
75,612.00
46,576.00
Unusual Expense
400.00
-
-
5,400.00
4,030.00
Non Operating Income/Expense
-
4.00
20.00
164.00
36.00
Pretax Income
29,044.00
49,520.00
73,144.00
82,059.00
50,908.00
Income Tax
-
-
75.00
201.00
67.00
Consolidated Net Income
29,044.00
49,520.00
73,219.00
82,260.00
50,975.00
Net Income
29,044.00
49,520.00
73,219.00
82,260.00
50,975.00
Net Income After Extraordinaries
29,044.00
49,520.00
73,219.00
82,260.00
50,975.00
Net Income Available to Common
29,044.00
49,520.00
73,219.00
82,260.00
50,975.00
EPS (Basic)
1.80
2.19
2.70
2.56
1.43
Basic Shares Outstanding
16,160.00
22,647.00
27,085.00
32,148.00
35,675.00
EPS (Diluted)
1.80
2.19
2.70
2.56
1.43
Diluted Shares Outstanding
16,160.00
22,647.00
27,085.00
32,148.00
35,675.00
EBITDA
28,503.00
47,483.00
70,713.00
73,374.00
44,926.00
Non-Operating Interest Income
90.00
-
436.00
659.00
752.00
Equity in Affiliates (Pretax)
-
1,583.00
1,561.00
1,542.00
1,018.00

About Ovascience

View Profile
Address
9 Fourth Avenue
Waltham Massachusetts 02451
United States
Employees -
Website http://www.ovascience.com
Updated 09/14/2018
OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H.